دورية أكاديمية
Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1 -Associated Episodic Ataxia and a Comprehensive Review of the Literature.
العنوان: | Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1 -Associated Episodic Ataxia and a Comprehensive Review of the Literature. |
---|---|
المؤلفون: | Lauxmann S; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; Institute of Neurobiology, University of Tübingen, Tübingen, Germany., Sonnenberg L; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; Institute of Neurobiology, University of Tübingen, Tübingen, Germany.; Bernstein Center for Computational Neuroscience Tübingen, Tübingen, Germany., Koch NA; Institute of Neurobiology, University of Tübingen, Tübingen, Germany.; Bernstein Center for Computational Neuroscience Tübingen, Tübingen, Germany., Bosselmann C; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Winter N; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Schwarz N; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Wuttke TV; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; Department of Neurosurgery, University of Tübingen, Tübingen, Germany., Hedrich UBS; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Liu Y; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Lerche H; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Benda J; Institute of Neurobiology, University of Tübingen, Tübingen, Germany.; Bernstein Center for Computational Neuroscience Tübingen, Tübingen, Germany., Kegele J; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. |
المصدر: | Frontiers in neurology [Front Neurol] 2021 Sep 09; Vol. 12, pp. 703970. Date of Electronic Publication: 2021 Sep 09 (Print Publication: 2021). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation, 2010]- |
مستخلص: | Introduction: Among genetic paroxysmal movement disorders, variants in ion channel coding genes constitute a major subgroup. Loss-of-function (LOF) variants in KCNA1 , the gene coding for K Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Lauxmann, Sonnenberg, Koch, Bosselmann, Winter, Schwarz, Wuttke, Hedrich, Liu, Lerche, Benda and Kegele.) |
References: | Neurology. 2004 Jan 13;62(1):17-22. (PMID: 14718690) J Neurol. 2011 Feb;258(2):273-6. (PMID: 20852877) Neurology. 2010 Mar 9;74(10):839-45. (PMID: 20211908) Neurology. 2011 Jul 19;77(3):269-75. (PMID: 21734179) J Pharmacol Exp Ther. 2001 Oct;299(1):227-37. (PMID: 11561084) Br J Pharmacol. 2023 Apr;180(8):1038-1055. (PMID: 36321697) Am J Hum Genet. 2000 May;66(5):1531-9. (PMID: 10762541) Mov Disord. 2001 Nov;16(6):1110-4. (PMID: 11748743) Expert Opin Pharmacother. 2012 Aug;13(12):1807-16. (PMID: 22783830) Anesthesiology. 1996 Sep;85(3):626-34. (PMID: 8853094) Glia. 2017 Feb;65(2):388-400. (PMID: 27859594) J Physiol. 2006 Aug 1;574(Pt 3):819-34. (PMID: 16728453) Pediatr Neurol. 2017 Feb;67:111-112. (PMID: 28065826) Nat Neurosci. 2003 Apr;6(4):378-83. (PMID: 12612586) Mov Disord Clin Pract. 2019 Dec 06;7(1):104-106. (PMID: 31970223) Nat Genet. 1994 Oct;8(2):136-40. (PMID: 7842011) Eur J Neurosci. 1995 Nov 1;7(11):2189-205. (PMID: 8563969) Int J Mol Sci. 2020 Oct 14;21(20):. (PMID: 33066705) Neurol Clin Pract. 2019 Dec;9(6):503-504. (PMID: 32042491) Neurology. 2012 Nov 20;79(21):2115-21. (PMID: 23077024) J Pharmacol Exp Ther. 1997 Sep;282(3):1280-90. (PMID: 9316836) Eur J Pharmacol. 1991 Feb 7;193(2):223-9. (PMID: 2050198) Lancet Neurol. 2016 Jul;15(8):789. (PMID: 27302353) Neuropediatrics. 2019 Oct;50(5):308-312. (PMID: 31226716) Neurology. 2016 Nov 8;87(19):1975-1984. (PMID: 27733563) Neurology. 2004 Jul 27;63(2):345-7. (PMID: 15277633) Neurology. 2010 Oct 19;75(16):1454-8. (PMID: 20956790) J Neurol Sci. 1975 May;25(1):109-18. (PMID: 1170284) Eur J Neurosci. 2008 May;27(10):2501-14. (PMID: 18445055) Ann N Y Acad Sci. 1991;627:277-90. (PMID: 1883139) J Neurol. 2010 Aug;257(8):1369-72. (PMID: 20352251) Brain. 1990 Oct;113 ( Pt 5):1361-82. (PMID: 2245301) Life Sci. 2008 Jan 2;82(1-2):11-20. (PMID: 18068197) Brain Commun. 2020 Mar 04;2(1):fcaa022. (PMID: 32954283) Sci Rep. 2017 Oct 23;7(1):13855. (PMID: 29062094) J Neurol. 1995 May;242(5):344-7. (PMID: 7643145) Neurol Neuroimmunol Neuroinflamm. 2018 Dec 24;6(2):e536. (PMID: 30697586) J Neurol Sci. 2010 Apr 15;291(1-2):30-6. (PMID: 20129625) J Neurol. 2016 Feb;263(2):334-343. (PMID: 26645390) Epilepsia Open. 2020 Jan 22;5(1):86-96. (PMID: 32140647) Nat Genet. 1997 Jan;15(1):62-9. (PMID: 8988170) Neurology. 2005 Sep 27;65(6):944-6. (PMID: 16186543) Neurol Neuroimmunol Neuroinflamm. 2017 Jun 14;4(4):e371. (PMID: 28638854) Pediatr Neurol. 2014 Jan;50(1):99-100. (PMID: 24200040) Neurology. 2010 Jul 27;75(4):367-72. (PMID: 20660867) Eur J Paediatr Neurol. 2019 May;23(3):438-447. (PMID: 30928199) Front Neurol. 2021 Mar 23;12:648031. (PMID: 33833732) Ann Clin Transl Neurol. 2020 Apr;7(4):565-572. (PMID: 32162847) Arch Neurol. 1996 Apr;53(4):338-44. (PMID: 8929156) Brain. 2007 Oct;130(Pt 10):2484-93. (PMID: 17575281) Hum Mutat. 2015 Aug;36(8):753-7. (PMID: 25864427) CNS Neurosci Ther. 2015 Mar;21(3):262-70. (PMID: 25495717) Exp Neurol. 1997 Sep;147(1):115-22. (PMID: 9294408) Nat Commun. 2016 Jul 06;7:12102. (PMID: 27381274) Neuroscience. 1998 Aug;85(3):931-8. (PMID: 9639285) Br J Pharmacol. 1997 Jan;120(2):225-30. (PMID: 9117114) Neuron. 1992 Jun;8(6):1055-67. (PMID: 1610565) Pediatr Neurol. 2016 Jun;59:71-75.e1. (PMID: 27091223) Cell J. 2013 Summer;15(2):98-107. (PMID: 23862110) Arch Neurol. 2007 May;64(5):749-52. (PMID: 17502476) Eur J Neurosci. 2000 Oct;12(10):3567-74. (PMID: 11029626) Lancet Neurol. 2015 Oct;14(10):968-9. (PMID: 26321319) Brain. 2015 Feb;138(Pt 2):371-87. (PMID: 25472797) Lancet Neurol. 2015 Oct;14(10):985-91. (PMID: 26321318) Neurotherapeutics. 2007 Apr;4(2):258-66. (PMID: 17395136) Neurology. 2005 Jul 12;65(1):156-8. (PMID: 16009908) Neurology. 2001 Oct 23;57(8):1499-502. (PMID: 11673600) Brain. 2012 Nov;135(Pt 11):3416-25. (PMID: 23107647) Biol Cybern. 2008 Nov;99(4-5):427-41. (PMID: 19011929) Brain. 2015 Oct;138(Pt 10):e384. (PMID: 25842392) Shinrigaku Kenkyu. 1989 Oct;60(4):245-52. (PMID: 2622103) Arch Neurol. 1963 May;8:471-80. (PMID: 13944410) Early Hum Dev. 1999 Mar;54(2):103-16. (PMID: 10213289) Drugs Context. 2019 Mar 11;8:212576. (PMID: 30891074) Neurosci Lett. 2000 Mar 10;281(2-3):75-8. (PMID: 10704746) Front Cell Neurosci. 2019 Aug 20;13:358. (PMID: 31481875) Brain. 2014 Apr;137(Pt 4):1009-18. (PMID: 24578548) Arch Neurol. 2009 Jan;66(1):97-101. (PMID: 19139306) Neurosci Lett. 2015 Mar 30;591:192-196. (PMID: 25703221) J Neurophysiol. 2007 Nov;98(5):2683-92. (PMID: 17855588) Neurology. 2005 Aug 23;65(4):529-34. (PMID: 16116111) Eur J Hum Genet. 2014 Apr;22(4):505-10. (PMID: 23982692) PLoS Genet. 2020 Mar 16;16(3):e1008625. (PMID: 32176688) J Hum Genet. 2018 Feb;63(2):207-211. (PMID: 29208948) J Neurosci. 1994 Aug;14(8):4588-99. (PMID: 8046438) Epilepsia. 2019 Sep;60(9):1881-1894. (PMID: 31468518) Brain. 1999 May;122 ( Pt 5):817-25. (PMID: 10355668) Ann N Y Acad Sci. 2008 Oct;1142:250-3. (PMID: 18990130) J Neurophysiol. 2012 Jan;107(1):484-92. (PMID: 22013234) J Neurol Sci. 2014 Jun 15;341(1-2):85-7. (PMID: 24780438) Dev Med Child Neurol. 2012 Sep;54(9):863-6. (PMID: 22320677) PLoS One. 2011 Apr 25;6(4):e18681. (PMID: 21541342) J Physiol. 2010 Jun 1;588(Pt 11):1905-13. (PMID: 20156848) Prog Neurobiol. 2001 Sep;65(1):1-105. (PMID: 11369436) Sci Rep. 2017 Oct 24;7(1):13913. (PMID: 29066757) Br J Pharmacol. 2014 Feb;171(4):1054-67. (PMID: 24283699) |
فهرسة مساهمة: | Keywords: KCNA1; KV1.1; conduction-based model; episodic ataxia; precision medicine; riluzole; sodium channel blockers; voltage-gated potassium channels |
تواريخ الأحداث: | Date Created: 20210927 Latest Revision: 20240407 |
رمز التحديث: | 20240407 |
مُعرف محوري في PubMed: | PMC8459024 |
DOI: | 10.3389/fneur.2021.703970 |
PMID: | 34566847 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!